- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01405339
Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray
The Effect of Budesonide Spray Via Mucosal Atomization Device on the Hypothalamic-Pituitary Axis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- ENT Clinic, St. Paul's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 19 years of age or older
- Diagnosed with CRS with or without polyps
- Awaiting for Functional Endoscopic Sinus Surgery
- Give consent on their own
Exclusion Criteria:
Concurrent or recent use (within the past 30 days) of systemic corticosteroids
- History of pituitary disease
- Morbid obesity (body mass index [calculated as weight in kilograms divided by height in meters squared]
Concurrent or recent use of medications that accelerate the clearance of cortisol:
o Such as dilantin, rifampin, amphetamines, or lithium carbonate
Concurrent use of medications that interfere with the production of cortisol:
o Such as ketoconazole, amphotericin B, bupropion, Echinacea, fluoroquinolones, itraconazole, licorice
- Use of oral contraception
- Use of female or male hormone therapy
- Known hypersensitivity to cortisol, corticotropin, or cosyntropin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Budesonide via MAD
The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD).
Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
|
The use of pulmicort via MAD once a day for a total of 30 days.
|
Active Comparator: Budesonide via Sinus Rinse Bottle
Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
|
The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cosyntropin testing and blood work for quantification of plasma budesonide and plasma cortisol.
Time Frame: Participants will be followed for 30 days.
|
Participants will be followed for 30 days.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
SNOT-22 questionnaire to measure subjective perspective.
Time Frame: Participants will be followed for the duration of post op standard of care, an expected average of 6 months.
|
Participants will be followed for the duration of post op standard of care, an expected average of 6 months.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Lund VJ, Black JH, Szabo LZ, Schrewelius C, Akerlund A. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. Rhinology. 2004 Jun;42(2):57-62.
- Sachanandani NS, Piccirillo JF, Kramper MA, Thawley SE, Vlahiotis A. The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2009 Mar;135(3):303-7. doi: 10.1001/archoto.2008.555.
- Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 2):200-9. doi: 10.1016/s0091-6749(99)70062-x.
- Bhalla RK, Payton K, Wright ED. Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: lack of significant adrenal suppression. J Otolaryngol Head Neck Surg. 2008 Dec;37(6):821-5.
- Kanowitz SJ, Batra PS, Citardi MJ. Topical budesonide via mucosal atomization device in refractory postoperative chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008 Jul;139(1):131-6. doi: 10.1016/j.otohns.2008.03.009.
- Thamboo A, Manji J, Szeitz A, Santos RD, Hathorn I, Gan EC, Alsaleh S, Javer AR. The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol. 2014 May;4(5):397-402. doi: 10.1002/alr.21280. Epub 2014 Jan 21.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Paranasal Sinus Diseases
- Nose Diseases
- Sinusitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
Other Study ID Numbers
- PSMAD2011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Rhinosinusitis
-
Unity Health TorontoCompletedChronic RhinosinusitisCanada
-
University of MiamiCompleted
-
Medtronic Surgical TechnologiesCompleted
-
University of MichiganNeilMed PharmaceuticalsCompletedChronic RhinosinusitisUnited States
-
Odense University HospitalCompleted
-
Taichung Veterans General HospitalCompletedPostoperative Care | Chronic RhinosinusitisTaiwan
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
-
Washington University School of MedicineCompletedChronic Rhinosinusitis (Diagnosis) | Allergic Rhinosinusitis | Chronic Eosinophilic RhinosinusitisUnited States
-
Icahn School of Medicine at Mount SinaiTivic Health SystemsRecruiting
Clinical Trials on Mucosal Atomization Device (MAD)
-
Hannover Medical SchoolCompletedEqually of Delivery Systems of Local Anesthesia in BronchoscopyGermany
-
State University of New York - Upstate Medical...CompletedDrug Overdose
-
Rabin Medical CenterSipNoseUnknownProcedural Sedation | Intra-nasal Delevery DeviceIsrael
-
Albert Einstein College of MedicineNational Institute on Aging (NIA)CompletedPost-operative Delirium | Post-operative Cognitive DeclineUnited States
-
St. Paul's Hospital, CanadaUnknown
-
St. Paul's Hospital, CanadaUnknownChronic Rhinosinusitis With Nasal Polyps | Allergic Fungal Sinusitis
-
ethisch.comite@uza.beCompletedObstructive Sleep Apnea SyndromeBelgium
-
University of AlbertaRecruitingObstructive Sleep ApneaCanada
-
University Hospital, AntwerpCompletedObstructive Sleep Apnea SyndromeBelgium
-
Hospital de Clinicas de Porto AlegreFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil; Conselho...UnknownHypertension | Cardiovascular Disease | Obstructive Sleep ApneaBrazil